Tevogen Bio Holdings Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tevogen Bio Holdings Inc. (TVGN) on April 2, 2024, covering events occurring on March 27 and March 28, 2024. The filing details the amendment of a securities purchase agreement and the creation of a new class of preferred stock.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. The primary financial activity reported is a capital raise:
- Investment Amount: $6.0 million aggregate purchase price.
- Instrument: 600 shares of Series A-1 Preferred Stock.
- Price Per Share: $10,000.
- Dividend Rate: 5% cumulative annual dividend, increasing by 2% annually, capped at 15%.
- Conversion: Convertible into 600,000 shares of Common Stock at the holder's election.
- Investor: An entity associated with Dr. Manmohan Patel, an existing beneficial owner of more than 5% of the company's common stock.
Material Changes Versus Prior Period
The transaction represents a material amendment to a February 14, 2024, agreement. The original agreement involved the purchase of 500 shares of Series A Preferred Stock for $2.0 million. The March 27, 2024, Amended and Restated Securities Purchase Agreement increased the investment to 600 shares of Series A-1 Preferred Stock for $6.0 million, tripling the capital commitment.
Terms, Rights, and Contingencies
The Series A-1 Preferred Stock includes specific rights and contingencies:
- Call Right: The Company may call the stock at $10,000 per share plus accrued dividends if the 20-day volume-weighted average price of Common Stock exceeds $5.00 and a resale registration statement is effective.
- Liquidation Preference: Ranks pari passu with Series A Preferred Stock and senior to Common Stock. Holders receive the greater of the Original Issue Price plus accrued dividends or the as-converted value.
- Voting Rights: Non-voting, except as required by law or specified in the Certificate of Designation.
- Protective Provisions: The Company cannot amend its charter or bylaws in a manner adverse to the Series A-1 Preferred Stock without the consent of holders of 50.1% of such stock.
- Regulatory Status: The transaction is exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the effective status of the resale registration statement required to trigger the Company's call right.
- Confirm the current volume-weighted average price of TVGN Common Stock relative to the $5.00 call threshold.
- Review the impact of the 5% to 15% cumulative dividend obligation on future cash flow and liquidity.
- Assess the dilution impact of the potential conversion of 600,000 shares of Common Stock.
- Confirm the identity and relationship of the investor entity associated with Dr. Manmohan Patel.